论文部分内容阅读
前列腺癌已经成为全世界男性最常见的癌症之一,目前临床采用的手术、化疗等传统治疗手段存在前列腺特异性抗原(Prostate specific antigen,PSA)复发、癌细胞转移等缺陷。PROSTVAC~疫苗的研发为前列腺癌的治疗提供了一种新的思路。PROSTVAC~是一种由导入了PSA和三合一共刺激分子(Triad of costimulatory molecules,TRICOM)基因的重组痘苗病毒和重组鸡痘病毒组成的疫苗。临床前研究和I期临床研究分别证明了PROSTVAC~的免疫机理和安全性、耐受性;Ⅱ期临床研究证明了PROSTVAC~的有效性和耐受性,能够延长前列腺癌患者的总生存期(Overall survival,OS)达9个月左右;PROSTVAC~的Ⅲ期临床研究目前正在进行中,研究结果预计于2017年初发布。PROSTVAC~作为一种治疗前列腺癌的新型免疫疗法具有很好的前景。
Prostate cancer has become one of the most common cancers in men around the world. At present, the traditional treatment methods such as surgery and chemotherapy in clinic have the defects of recurrence of prostate-specific antigen (PSA) and cancer metastasis. PROSTVAC ~ vaccine research and development for the treatment of prostate cancer provides a new idea. PROSTVAC ~ is a vaccine consisting of recombinant vaccinia virus and recombinant fowlpox virus transduced with PSA and triad of costimulatory molecules (TRICOM). Preclinical studies and phase I clinical studies have demonstrated the immunological mechanism and safety of PROSTVAC-, respectively. Phase Ⅱ clinical studies have demonstrated the effectiveness and tolerability of PROSTVAC-, prolonging the overall survival of patients with prostate cancer (Overall survival, OS) for about 9 months; PROSTVAC ~ Ⅲ phase III clinical studies are currently underway, the results are expected to be released in early 2017. PROSTVAC ~ as a new type of immunotherapy for the treatment of prostate cancer has a good prospect.